南新制药(688189) - 2021 Q3 - 季度财报

Financial Performance - The company's operating revenue for the third quarter was ¥154,484,830.03, a decrease of 42.48% compared to the same period last year[5] - The net profit attributable to shareholders was ¥8,794,648.91, down 59.20% year-on-year[5] - The basic earnings per share were ¥0.0628, reflecting a decline of 59.20% compared to the previous year[6] - The net profit excluding non-recurring gains and losses was ¥8,257,893.40, down 52.97% year-on-year[5] - Total operating revenue for the first three quarters of 2021 was CNY 621,710,154.59, a decrease of 26.8% compared to CNY 849,142,132.03 in the same period of 2020[19] - Net profit for the first three quarters of 2021 was CNY 53,104,254.92, a decline of 29.2% from CNY 74,769,473.79 in 2020[20] - Earnings per share for the first three quarters of 2021 was CNY 0.3839, compared to CNY 0.5538 in the same period of 2020[21] Research and Development - Research and development expenses totaled ¥17,673,886.49, a decrease of 46.03% from the same period last year, representing 11.44% of operating revenue[6] - The company is continuing to advance its major R&D projects, including inhalation solutions and dry suspensions, despite reduced R&D spending in the current period[10] - Research and development expenses for the first three quarters of 2021 were CNY 53,521,947.60, a decrease of 23.5% from CNY 69,933,608.52 in 2020[19] Cash Flow and Assets - The net cash flow from operating activities was negative at -¥193,890,789.30, indicating significant cash outflow[6] - Operating cash inflow for the period was $449,822,839.79, a decrease from $665,525,044.40 in the previous period[24] - Net cash flow from operating activities was -$193,890,789.30, compared to -$176,913,789.24 in the prior period[24] - Cash inflow from investment activities totaled $1,832,299,959.54, significantly higher than $757,436.99 in the previous period[25] - The ending cash and cash equivalents balance was $320,141,775.85, compared to $1,053,207,485.20 at the end of the previous period[25] - Total assets increased to ¥2,343,515,269.37, marking a growth of 12.34% compared to the end of the previous year[6] - Total current assets as of September 30, 2021, amount to ¥1,972,906,560.02, an increase from ¥1,713,143,799.07 in the previous year[15] - Total assets as of September 30, 2021, are ¥2,343,515,269.37, compared to ¥2,086,018,842.19 at the end of 2020[15] Shareholder Information - Total number of common shareholders at the end of the reporting period is 7,310[12] - The largest shareholder, Hunan Xiangtou Holding Group Co., Ltd., holds 40,000,000 shares, accounting for 28.57% of total shares[12] - The total number of shares held by the top 10 shareholders is 92,000,000, representing a significant concentration of ownership[12] Liabilities and Financial Position - Total liabilities as of the reporting date were CNY 711,999,937.86, an increase of 52.5% from CNY 466,867,765.60 in the previous year[19] - Short-term borrowings have significantly increased to ¥465,000,000.00 from ¥235,248,875.00, indicating a rise of 97.5%[15] - Total equity attributable to shareholders was CNY 1,608,819,430.90, slightly up from CNY 1,595,817,614.62 in the previous year[19] - Financial expenses increased to CNY 19,031,768.56 in 2021, compared to CNY 3,578,128.44 in the same period of 2020[19] Market and Operational Insights - The company attributed the decline in revenue and profit to ongoing impacts from the pandemic on marketing and logistics[10] - The company did not report any significant new product launches or market expansions during this period[26]